COVID-19 pneumonia. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Patients in dexamethasone group receive intravenous dexamethasone (manufactured by Abouraihan Pharmaceutical Company) at dose of 20 mg/day for day's one to five and
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients between 18 and 65 years old Laboratory COVID-19 confirmed with RT-PCR Mild to moderately ill patients Patients with PaO2/FiO2 between 100-300 Signed the consent form
Exclusion criteria
Exclusion criteria: Acute or chronic renal impairment (Creatinin rise more than 3 units in the last 48 hours and/or GFR less than 30 mL/min) Chronic liver disease (Rise in LFTs more than 5 times and/or 3 times rise in LFTs in symptomatic patients and/or Child pugh C,D) Allergy to corticosteriods while being injected with extravasation and signs of anaphylactic shock. Patients with hyperglycemia Pregnancy and lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Need for invasive mechanical ventilation. Timepoint: Daily. Method of measurement: Medical record.;Death. Timepoint: At the end of the study. Method of measurement: Medical record. | — |
Secondary
| Measure | Time frame |
|---|---|
| Weaning from oxygen support. Timepoint: Daily. Method of measurement: Medical record.;Length of hospital stay. Timepoint: At the end of the study. Method of measurement: Medical record.;Lung radiology changes. Timepoint: At admission time and seven and 14 days later. Method of measurement: At admission time and seven and 14 days later. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Mohammadreza Hashemian
Shahid Beheshti University of Medical Sciences
Outcome results
None listed